Abliva AB

Pharming Group to Acquire Abliva in $66.1 Million Deal, Bolstering Mitochondrial Disease Pipeline

- Pharming Group N.V. has announced a public cash offer to acquire Abliva AB for approximately US$66.1 million, strengthening its pipeline. - Abliva's lead product, KL1333, is in a pivotal clinical trial for primary mitochondrial disease (PMD) driven by mitochondrial DNA mutations. - KL1333 has shown positive clinical effects and has received Fast Track and Orphan Drug designations, targeting over 30,000 patients. - The acquisition, funded by Pharming's existing cash, aims for a U.S. launch of KL1333 in 2028, pending regulatory approvals.